Startups

Normunity: $75 Million (Series B) Raised For Broadening Pipeline Of Novel Anti-Cancer Therapies

By Amit Chowdhry ● Jan 13, 2025

Normunity, a biotechnology company creating novel anti-cancer therapies, announced today that it closed a Series B funding round of $75 million. The funding was co-led by Samsara BioCapital and Enavate Sciences, alongside other new investors Regeneron Ventures, Pfizer Ventures and YK Bioventures, as well as existing investors Canaan Partners, Sanofi Ventures, Taiho Ventures, Osage Venture Partners, HongShan Capital Group, and Connecticut Innovations. And the Board of Directors will be expanded to include David Parry, PhD (Samsara), Sara Nayeem, MD (Enavate), and Marie-Clare Peakman, MD (Pfizer Ventures).

Tidal Cyber Buying Zero-Shot Security

By Amit Chowdhry ● Jan 13, 2025

Tidal Cyber, the Threat-Informed Defense company, announced the acquisition of Zero-Shot Security, the creator of an innovative artificial intelligence (AI) solution that simplifies and speeds the processing and analysis of threat intelligence.

Holly: AI-Based Government Hiring Platform Raises $2.2 Million

By Amit Chowdhry ● Jan 13, 2025

Holly, an AI-based platform modernizing government hiring, announced the closing of its $2.2 million oversubscribed pre-seed round, led by J2 Ventures with participation from Roble Ventures, Gaingels, and notable angel investors. And the funding will support Holly's platform as it works to solve the million-job government workforce vacancy crisis.

Tune Therapeutics: Over $175 Million (Series B) Raised For Advancing Field-Leading Epigenome Editing Programs

By Amit Chowdhry ● Jan 13, 2025

Leading epigenome editing company Tune Therapeutics announced the completion of over $175 million in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures, and Hevolution Foundation.

A2 Biotherapeutics: $80 Million (Series C) Raised For Advancing Clinical Development Of Precision Cell Therapies

By Amit Chowdhry ● Jan 12, 2025

A2 Biotherapeutics - a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to target tumor cells and protect normal cells selectively - announced the closing of its $80 million Series C financing round, supported by a syndicate of investors that includes The Column Group and Samsara BioCapital.

Valspring Capital: Fund I Closed Above Target At $255 Million

By Amit Chowdhry ● Jan 12, 2025

Valspring Capital, a healthcare-focused growth equity firm, announced the closing of its debut fund, Valspring Capital Fund I, above its target at $255 million. Launched in 2022 by a team spun off from Bain Capital Ventures to pursue healthcare investments with the firm’s support, the Valspring team will seek to invest primarily in growth-stage companies in the healthcare industry, focusing on the information technology, technology-enabled services, and services sectors within North America.

Phase Four: In-Space Propulsion Company Raises Series C

By Amit Chowdhry ● Jan 12, 2025

Phase Four, a leader in advanced in-space propulsion design and manufacturing, announced the first close of its Series C funding round, securing nearly 60% of the target raise with strong participation from new and existing investors. And the round is led by Artemis Group Capital, the Oklahoma-based investment firm helmed by former NASA Administrator Jim Bridenstine, emphasizing the growing confidence in Phase Four's innovative propulsion solutions.

RLTYco: $20 Million (Series A) Raised For Giving Agents Same-Day Commission Advances And Other Benefits

By Amit Chowdhry ● Jan 12, 2025

RLTYco, a New York-based full-service provider of comprehensive resources for real estate professionals, announced the closing of a $20 million Series A funding round led by Altriarch. The funding round also included participation from existing investors, including Andrew Dodge, entrepreneur and angel investor, Christopher Schmidt, Executive Vice President at Related Companies, and SERHANT. Ventures (SERHANT.’s education division that develops, creates, and produces resources and solutions for agents in today’s new marketplace). Ryan Serhant, CEO and founder of SERHANT., is a partner, advisor and ambassador via SERHANT. Ventures.

Grand Games: $30 Million (Series A) Raised To Accelerate Growth

By Amit Chowdhry ● Jan 12, 2025

Grand Games, a gaming studio behind the widely loved Magic Sort mobile game, announced it has raised a $30 million Series A round, marking its arrival as the latest up-and-coming studio to emerge from Istanbul, the gaming powerhouse that brought forth Dream Games and Peak Games. Balderton Capital led the round with participation from existing investors Bek Ventures (formerly known as Earlybird Digital East), Laton Ventures, and angel investor Mert Gür.

Oddball Raises Growth Investment From Falfurrias Management

By Amit Chowdhry ● Jan 12, 2025

Private equity firm Falfurrias Management Partners announced its growth investment in Oddball. This leading digital services agency transforms and modernizes how government organizations interact with their constituents.

Prudentia Sciences: AI-Based Life Sciences Marketplace Company Raises $7 Million

By Amit Chowdhry ● Jan 12, 2025

Prudentia Sciences, an AI-based technology platform for life sciences announced its public launch, supported by $7 million in funding. This funding round was led by GV, with participation from Iaso Ventures and Virtue.

Tenvie Therapeutics Raises $200 Million For Delivering Small Molecule Therapies

By Amit Chowdhry ● Jan 12, 2025

Advanced Ionics: Green Hydrogen Electrolyzer Company Raises $6.7 Million

By Amit Chowdhry ● Jan 12, 2025

Advanced Ionics, a developer of a new class of green hydrogen electrolyzers aimed at accelerating decarbonization, announced that it raised an additional $6.7 million in funding from strategic investors JERA, Lummus Venture Capital, the Argosy Foundation, and existing investors Clean Energy Venture Group and bp Ventures.

Absci Raising $20 Million From AMD

By Amit Chowdhry ● Jan 12, 2025

Absci Corporation, a data-first generative AI-based drug creation company, announced a strategic collaboration with AMD to deploy AMD Instinct accelerators and ROCm software to power critical AI drug discovery workloads, including Absci's advanced de novo antibody design models. And AMD will also make a $20 million investment in Absci, structured as a private investment in public equity (PIPE), highlighting the growing demand for innovative AI applications in drug discovery.

Vensana Capital: $425 Million Fund III Closed For Investing In Breakthrough Medical Technologies

By Amit Chowdhry ● Jan 12, 2025

Vensana Capital announced the closing of Vensana Capital III with $425 million in committed capital. This fund was oversubscribed at its hard cap with the support of the firm’s existing limited partners alongside select new institutional investors, and it brings Vensana’s total capital under management to about $1 billion.

Leyden Labs: $70 Million Secured For Advancing Intranasal Antibody Programs

By Amit Chowdhry ● Jan 12, 2025

Leyden Laboratories announced it has raised $70 million in funding to advance its Mucosal Protection Platform. This funding round was supported by co-leads ClavystBio and Polaris Partners, with participation by Qiming Venture Partners and existing investors. And the company’s syndicate of VC investors now includes GV (formerly Google Ventures), Casdin Capital, F-Prime Capital, ClavystBio, Polaris Partners, Qiming Venture Partners, Invus, Byers Capital / Brook Byers, Bluebird Ventures, and Softbank Vision Fund 2.

RyboDyn: $4 Million (Pre-Seed) Raised To Pioneer Development Of First-In-Class Immunotherapies

By Amit Chowdhry ● Jan 12, 2025

RyboDyn announced the discovery of a new proteome and the successful closing of a $4 million pre-seed financing round to advance its mission of targeting the dark proteome to develop novel immunotherapies. The funding round was co-led by Genedant Capital and SeaX Ventures, with significant participation from SOSV and Swell VC as part of the investment syndicate.

RheumaGen: Gene Therapy Company Raises $15 Million (Series A)

By Amit Chowdhry ● Jan 11, 2025

RheumaGen - a cell and gene therapy company engineering a new class of therapeutics for major autoimmune diseases - announced the closing of a $15 million Series A financing co-led by SPRIM Global Investments and William Taylor Nominees.

Red Rover Health: $4 Million (Seed) Raised To Advance Healthcare App Store Platform

By Amit Chowdhry ● Jan 10, 2025

Red Rover Health, a company that enables healthcare providers to integrate best of breed third-party solutions into their electronic health record (EHR) systems, has received $4 million in seed funding from NewShore Partners. The latest funding round gives Red Rover the capital to hire key talent to expand the core integration platform and scale operations.

Zeto: $31 Million (Series B) Raised For Transforming EEG Brain Monitoring

By Amit Chowdhry ● Jan 10, 2025

Zeto - a rapidly growing medical technology company transforming EEG diagnostics with its cutting-edge devices and AI-driven cloud platform, has announced the closing of a $31 million funding round.

Aspect Biosystems: $115 Million (Series B) Secured To Develop Bioprinted Tissue Therapeutics

By Amit Chowdhry ● Jan 10, 2025

Aspect Biosystems - a biotechnology company advancing the development of bioprinted tissue therapeutics as a new category in regenerative medicine - announced that it has closed a $115 million Series B funding round. This funding round was led by Dimension, a multistage investment firm dedicated to the interface of technology and the life sciences, with participation from existing and new investors, including Novo Nordisk, Radical Ventures, an undisclosed leading global investment firm, InBC, Pallasite Ventures, Pangaea Ventures, Rhino Ventures, and T1D Fund: A Breakthrough T1D Venture.

Nema Health: $14.5 Million (Series A) Raised For Expanding Virtual PTSD Treatment Model

By Amit Chowdhry ● Jan 10, 2025

Nema Health, a leading solution for virtual trauma and PTSD care, announced a $14.5 million Series A funding round led by Deerfield Management alongside new participant CVS Health Ventures (CVS Health's venture capital arm). And Nema's existing investors Optum Ventures, .406 Ventures, and GreyMatter also participated,

Gridware: Power Grid Monitoring Solution Provider Raises $26.4 Million (Series A)

By Amit Chowdhry ● Jan 10, 2025

Gridware - a continuous power grid monitoring solution provider - announced a Series A funding round of $26.4 million led by Sequoia Capital. The funding will enable Gridware to scale further production of Gridscope devices and the Gridware monitoring and analytics service, which provides continuous power grid monitoring 24 hours per day to help utilities prepare for and respond to a growing number of risks.

Signiant Raises Majority Growth Investment From Battery Ventures

By Amit Chowdhry ● Jan 10, 2025

Signiant, a leading provider of secure file transfer software for the media and entertainment industry, announced a majority growth investment from Battery Ventures. The terms of the deal were undisclosed.

Verdiva Bio: Cardiometabolic Company Raises Over $410 Million (Series A)

By Amit Chowdhry ● Jan 10, 2025

Verdiva Bio announced its launch as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other cardiometabolic disorders. And the company is advancing a portfolio of next-generation oral and injectable treatments with first-in-class or best-in-class potential. And Verdiva has launched with an oversubscribed Series A funding of $411 million, co-led by Forbion and General Atlantic, with additional participation from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital.

Oxford Cancer Analytics: $11 Million (Series A) Secured For Transforming Early Lung Cancer Detection And Enabling Curative Treatments

By Amit Chowdhry ● Jan 10, 2025

Oxford Cancer Analytics - a medical technology company developing blood tests for early cancer detection using advanced proteomics and AI - announced it has raised $11 million in Series A funding from global investors, such as in-field institutional investors in disease detection and diagnostics.

Geneoscopy: $105 Million (Series C) Raised For Developing Advanced Gastrointestinal Diagnostic Tests

By Amit Chowdhry ● Jan 10, 2025

Geneoscopy - a life sciences company focused on developing diagnostic tests for advancing gastrointestinal health - announced the closing of a Series C funding round raising $105 million. Bio-Rad Laboratories led the financing and was joined by Petrichor, Labcorp, Morningside Ventures, Lightchain Capital, NT Investments, Granger Management and Mercy Health, Tri Locum Partners, and others.

Frontier Direct Care: Employer-Funded Healthcare Leader Closes $20 Million (Series B)

By Amit Chowdhry ● Jan 10, 2025

Frontier Direct Care, a leading innovator in employer-funded healthcare, announced the initial closing of its $20 million Series B funding round, led by Mehshah Capital. This funding will accelerate the company's mission to transform healthcare by delivering affordable and high-quality care to employees and their families.

Scrum Ventures Closes New Tech Fund At $68 Million

By Amit Chowdhry ● Jan 10, 2025

Scrum Ventures, an early-stage venture capital firm, announced the closing of its first vertically focused tech fund Scrum Sports & Entertainment Fund I (SSE). This new fund, which closed at $68 million, invests in technology companies that support the growth of the sports and entertainment sector but also transcend the vertical and address market inefficiencies in other industries.

Relief Cardiovascular: $12 Million (Series A) Raised To Develop Transcatheter Implants

By Amit Chowdhry ● Jan 10, 2025

Relief Cardiovascular, an inQB8 Medical Technologies portfolio company pioneering innovative solutions for the management of heart failure, announced the closing of a $12 million Series A funding round. This funding round was co-led by Broadview Ventures and Advent Life Sciences, with participation from Pacific Health Investment, Heartwork Capital, and an undisclosed multinational strategy.